Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

Clinical Therapeutics

Volumn 32, Issue 7, 2010, Pages 1234-1251

  Farlow, Martin R ^a   Salloway, Stephen ^b   Tariot, Pierre N ^c   Yardley, Jane ^d   Moline, Margaret L ^e   Wang, Qin ^e   Brand Schieber, Elimor ^e   Zou, Heng ^e   Hsu, Timothy ^e   Satlin, Andrew ^e  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d EISAI CO LTD   (Japan)

^e EISAI INC   (United States)

Author keywords

Alzheimer's disease; Cognitive disorders; Dementia; Randomized controlled clinical trials

Indexed keywords

DONEPEZIL;

ADULT; AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; ASTHENIA; BODY WEIGHT; BRADYCARDIA; CAREGIVER; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLING; FATIGUE; FEMALE; HEADACHE; HUMAN; INCONTINENCE; INSOMNIA; LABORATORY TEST; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA; NEUROLOGIC EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINUS BRADYCARDIA; SOMNOLENCE; URINALYSIS; URINARY TRACT INFECTION; VITAL SIGN; VOMITING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; PIPERIDINES; SEVERITY OF ILLNESS INDEX;

EID: 77955253242     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.06.019     Document Type: Article

References (39)

1. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) 1994, American Psychiatric Association, APA, Washington, DC.
2. Reisberg B, Burns A, Brodaty H, et al. Diagnosis of Alzheimer's disease. Report of an International Psychogeriatric Association Special Meeting Work Group under the cosponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association. Int Psychogeriatr. 1997, 9(Suppl 1):11-38.
3. Aricept (donepezil hydrochloride) [prescribing information] Accessed June 8, 2010. http://www.pfizer.com/files/products/uspi_aricept.pdf.
4. Jann MW, Shirley KL, Small GW Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002, 41:719-739.
5. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 2004, 291:317-324. Memantine Study Group.
6. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease [published correction appears in Neurology. 2001;57:2153]. Neurology. 2001, 57:613-620. Donepezil MSAD Study Investigators Group.
7. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging. 2006, 10:417-429.
8. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study [published corrections appear in Lancet. 2006;386:1650 and Lancet. 2006;367: 1980]. Lancet. 2006, 367:1057-1065. Severe Alzheimer's Disease Study Group.
9. Xiong G, Doraiswamy PM Combination drug therapy for Alzheimer's disease: What is evidence-based, and what is not?. Geriatrics. 2005, 60:22-26.
10. Tariot PN, Yaari R Combination therapies for treating Alzheimer's disease. US Neurology. 2008, 4:31-33. Accessed February 15, 2010. http://www.touchneurology.com/articles/combination-therapies-treating-alzheimer-s-disease.
11. Mesulam M The cholinergic lesion of Alzheimer's disease: Pivotal factor or side show?. Learn Mem. 2004, 11:43-49.
12. Pappas BA, Bayley PJ, Bui BK, et al. Choline acetyltrans-ferase activity and cognitive domain scores of Alzheimer's patients. Neurobiol Aging. 2000, 21:11-17.
13. Imbimbo BP Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs. 2001, 15:375-390.
14. Shintani EY, Uchida KM Donepezil: An anticholinesterase inhibitor for Alzheimer's disease. Am J Health Syst Pharm. 1997, 54:2805-2810.
15. Kuhl DE, Minoshima S, Frey KA, et al. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol. 2000, 48:391-395.
16. Bohnen NI, Kaufer DI, Hendrickson R, et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2005, 76:315-319.
17. Folstein MF, Folstein SE, McHugh PR "Mini-mental state" A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975, 12:189-198.
18. Nozawa M, Ichimiya Y, Nozawa E, et al. Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan. Psychogeriatrics. 2009, 9:50-55.
19. Farlow MR Moderate to severe Alzheimer disease: Definition and clinical relevance. Neurology. 2005, 65(Suppl 3):S1-S4.
20. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984, 34:939-944.
21. Panisset M, Roudier M, Saxton J, Boller F Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol. 1994, 51:41-45.
22. Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment battery: Concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997, 11(Suppl 2):S51-S56.
23. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA Cornell Scale for Depression in Dementia. Biol Psychiatry. 1988, 23:271-284.
24. Radloff LS The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Appl Psychol Meas. 1977, 1:385-401.
25. Physicians' Desk Reference 2010, Thomson PDR, Montvale, NJ. 64th ed.
26. Joffres C, Graham J, Rockwood K Qualitative analysis of the clinician interview-based impression of change (Plus): Methodological issues and implications for clinical research. Int Psychogeriatr. 2000, 12:403-413.
27. Schneider LS, Olin JT Clinical global impressions in Alzheimer's clinical trials. Int Psychogeriatr. 1996, 8:277-288.
28. Schneider LS, Olin JT Clinical global impressions in Alzheimer's clinical trials. Int Psychogeriatr. 1996, 8:288-290. discussion.
29. Galasko D, Schmitt F, Thomas R, et al. Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. J Int Neuropsychol Soc. 2005, 11:446-453. Alzheimer's Disease Cooperative Study.
30. Dmitrienko A, Chuang-Stein C, D'Agostino R Pharmaceutical Statistics Using SAS: A Practical Guide 2007, SAS Institute Inc, Cary, NC.
31. Koch GG, Tangen CM, Jung JW, Amara IA Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them. Stat Med. 1998, 17:1863-1892.
32. Brodaty H, Corey-Bloom J, Potocnik FC, et al. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2005, 20:120-132.
33. Medical Dictionary for Regulatory Activities US Food and Drug Administration, [MedDRA Web site], Accessed June 21, 2010. http://www.meddramsso.com/.
34. Galasko D, Kershaw PR, Schneider L, et al. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease. J Am Geriatr Soc. 2004, 52:1070-1076.
35. Demers L, Oremus M, Perrault A, et al. Review of outcome measurement instruments in Alzheimer's disease drug trials: Psychometric properties of functional and quality of life scales. J Geriatr Psychiatry Neurol. 2000, 13:170-180.
36. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer's disease. Neurology. 2007, 69:459-469.
37. Homma A, Imai Y, Tago H, et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: Results from a 24-week, double-blind, placebocontrolled, randomized trial. Dement Geriatr Cogn Disord. 2008, 25:399-407.
38. Vellas B, Gauthier S, Allain H, et al. Consensus statement on dementia of Alzheimer type in the severe stage. J Nutr Health Aging. 2005, 9:330-338.
39. Whitehead A, Perdomo C, Pratt RD, et al. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: A meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry. 2004, 19:624-633.